Company Information

  

Address: 373 INVERNESS PARKWAY
SUITE 206 
City: ENGLEWOOD 
State: CO 
Zip Code: 80112 
Telephone: (720) 437-6580 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a commercial-stage specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs. We have multiple approved products on the market, and we seek to build a portfolio of novel therapeutics that serve large medical needs, across a range of conditions, through our in-house commercial team. Our commercial infrastructure consists of a U.S.-based specialty sales force and an international distribution network with presence in approximately fifty countries. We are currently concentrating on hypogonadism, male infertility and, recently, insomnia and plan to expand into other indications for which we believe there are significant medical needs. We acquired exclusive U.S. rights to Natesto┬« (testosterone) nasal gel, a novel formulation of testosterone delivered via a discreet, easy-to-use nasal gel, and we launched Natesto in the U.S. with our direct sales force in late summer 2016.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/201925.37NA0.07
12/201846.57NA0.02
09/201817.88NA0.15
06/2018-306.20NAN/E
03/2018-3508.00NAN/E

Key Financial Ratios and Statistics

FYE: 06/30

Profitability 2018 Leverage 2018
Net Inc/Comm Equity-0.11Total Liab/Total Assets0.36
Net Inc/Total Assets-0.48Total Liab/Inv Cap0.43
Net Inc/Inv Cap-0.58Total Liab/Comm Equity0.08
Pretax Inc/Net Sales-2.78Interest Coverage Ratio-12.59
Net Inc/Net Sales-2.78Curr Debt/EquityNA
Cash Flow/Net Sales-4.36LTD/Equity0.01
SG&A/NetSales4.84Total Debt/Equity0.01
Asset Utilization   Liquidity  
Net Receivables Turnover6.61Quick Ratio2.40
Inventory Turnover1.55Current Ratio2.79
Inventory Day Sales0.00Net Rec/Curr Assets0.06
Net Sales/Work Cap0.60Inv/Curr Assets0.14
Net Sales/PP&E16.74  

Income Statement (Millions)

  3/31/2019 12/31/2018 9/30/2018 6/30/2018
Total Revenues(Net Sales) 2.38 1.80 1.43 0.93
Cost of Goods Sold 0.62 0.53 0.41 0.24
Selling & Admin Exps 5.38 5.14 3.83 3.92
Operating Income -4.30 -4.55 -3.42 -3.83
Interest Exp NA -0.08 0.08 0.75
Pretax Income -4.50 -4.66 -3.45 0.55
Other Income -0.20 -0.18 0.05 5.12
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -4.50 -4.66 -3.45 0.55

Balance Sheet (Millions)

Assets 3/31/2019 12/31/2018 9/30/2018 6/30/2018
Cash & Short Term Investments 14.75 17.91 4.06 7.11
Receivables - Total 1.38 1.48 0.76 0.58
Inventories - Total 1.53 1.64 1.31 1.34
Total Current Assets 18.46 21.98 6.87 9.47
Net Property, Plant & Equipment 0.22 0.19 0.20 0.22
Total Assets 38.34 42.40 17.98 21.06
Liabilities        
Accounts Payable 3.69 4.05 3.34 2.85
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 4.50 4.66 3.59 3.39
Long-Term Debt 5.16 5.06 0.05 0.09
Total Liabilities 22.30 22.50 7.85 7.64
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.00 0.00 0.00 0.00
Retained Earnings -91.86 -87.36 -82.70 -79.26
Treasury Stock NA NA NA NA
Total Stockholders' Equity 16.04 19.90 10.13 13.42
Total Liabilities and Stockholders' Equity 38.34 42.40 17.98 21.06

Cash Flow Summary (Millions)

Categories 3/31/2019 12/31/2018 9/30/2018 6/30/2018
Net Cash Provided by Operating Activities -3.31 -4.30 -2.74 -4.54
Net Cash Provided by Investing Activities -0.11 -0.56 -0.30 -0.40
Net Cash Provided by Financing Activities 0.26 18.70 0.00 -0.02

Annual Summary Data (Millions)

Year Sales Net Income EPS
06/20140.00-0.06--
06/20150.26-7.72--
06/20162.56-28.18--
06/20173.22-22.51--
06/20183.66-10.19-306.20
Growth Rates677.81----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/19273,19819.20




Report Date : 9/9/2019

Powered By Edgar Online © 2019EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.